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INTRODUCTION
Opioids are commonly used for the management of
intraoperative and postoperative pain. Systemic
administration of high doses of opioids is associated
with a variety of adverse reactions such as pruritis,
sedation, nausea, vomiting, respiratory depression and
constipation.1 The development of multimodal or
balanced analgesia techniques for postoperative
analgesia, involving the use of combinations of drugs,
has helped to improve quality of analgesia with
reduction in incidence and severity of these side
effects.2 Opioid consumption can be significantly
reduced by combining them with non-opioid analgesic in
pain therapy. Non-steroidal anti-inflammatory drugs
(NSAIDs) effectively reduce opioid consumption by 20-
30% to improve analgesia and reduce side effects.3,4 A
combined therapy of opioids and NSAIDs could result in
synergistic analgesia by acting through different
mechanisms.5
In postoperative pain management, tramadol is an
alternative agent to morphine for Patient  Controlled
Intravenous Analgesia (PCIA) treatment. Tramadol is a
centrally acting analgesic with opioid and non-opioid
modes of action. It is a weak µ receptors agonist and its
analgesic activity is mostly via inhibition of re-uptake of
neurotransmitters like norepinephrine and serotonin in
the central nervous system.6 The advantage of tramadol
over traditional opioids is minimal potential for tolerance
and respiratory depression but also has nausea and
vomiting as side effects which affect physician and
patients’ satisfaction.7
NSAIDs are mainly used as co-analgesics for the
treatment of postoperative pain in moderate to major
surgery. They block the synthesis of prostaglandins by
inhibiting Cyclooxygenase (COX), thereby reducing
production of mediators of the acute inflammatory
response. By decreasing the inflammatory response to
surgical trauma, NSAIDs have been supposed to reduce
peripheral nociception. More recent studies also
suggest that the central response to painful stimuli may
be modulated by NSAIDs-induced inhibition of prosta-
glandin synthesis in the spinal cord.1
There has been little published work on the synergism of
tramadol (opioid) and diclofenac (NSAIDs). The purpose
of this study was to determine whether addition of
diclofenac suppository reduced tramadol consumption
and side effects in posthysterectomy patients.
ABSTRACT
Objective: To determine reduction in dose of tramadol and side effects in posthysterectomy patients on addition of
diclofenac on rectal suppository.
Study Design: Randomized double blinded placebo controlled study.
Place and Duration of Study: The Aga Khan University Hospital, Karachi, Pakistan, from August 2004 to January 2006.
Methodology: Seventy ASA I and II females, aged 20 and above, who underwent elective abdominal hysterectomy, were
included in this study. Patients received identical looking suppository of either 100 mg diclofenac sodium or placebo after
induction of anaesthesia and then 12 hourly for 24 hours. General anaesthesia was standardized and tramadol was given
by patient controlled intravenous analgesia delivery system in the recovery. 
Results: The mean dose + SD of tramadol used in first 24 hours was found to be 317 +153 mg in the placebo-tramadol
group compared to 258 +192 mg in the diclofenac-tramadol group (p = 0.15, 95% CI = 1.24 to -1.34, 6.63). Seventeen
(49 %) patients in the placebo-tramadol group and 14 (40%) in the diclofenac-tramadol group used rescue analgesia
(p=0.47). Sedation score was similar in both the groups and there was no difference in the incidence of nausea and
vomiting and use of antiemetics between the groups.
Conclusion: This study did not show any reduction in tramadol consumption, given via patient controlled intravenous
analgesia when rectal suppository of 100 mg diclofenac was added.
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METHODOLOGY
The study was conducted in the Aga Khan University
Hospital, Karachi, from August 2004 to January 2006.
After obtaining institutional ethical committee approval
and written informed consent from patients, 70 ASA I
and II female patients, aged 20 and above, undergoing
elective abdominal hysterectomy under Pfannenstiel
incision technique, were recruited in this randomized
double blind placebo controlled trial. Exclusion criteria
were hysterectomy under midline incision technique,
emergency surgery, surgery for malignancy, history of
chronic pain, peptic ulceration, bleeding disorders,
impaired renal or hepatic function, sensitivity to NSAID
or opioids, and patients’ inability to use Patient-
Controlled Analgesia (PCA).
Patients were randomly divided into two groups to either
receive diclofenac suppository or a placebo after
induction of anaesthesia. The randomization was done
by the pharmacy department. Patients were allocated
randomly according to a list of random numbers into two
groups in sealed opaque envelopes. The suppositories
were provided by the pharmacy and an appropriate
code number (case 1, case 2 and so on) was assigned.
The investigators were unaware of the group. During
pre-operative assessment, the patient were instructed
regarding Verbal Rating Score (VRS) of pain (0 = no
pain, 1 = mild pain, 2 = moderate pain and 3 = severe
pain)8 and were also familiarized with the use of PCA
pump to minimize pain (obtaining a score less than 2). 
The number of patients recruited was based on
detecting a difference of 30% in total tramadol
consumption between the two groups in 24 hours, an
alpha (α) error of 5% and β error of 20% at a standard
deviation of 166. All the patients were then
premedicated with 7.5 mg midazolam tablet half to one
hour prior to surgery. 
On arrival in the operating room, routine monitoring i.e.
electrocardiogram, non-invasive blood pressure and
pulse oximetry was instituted. A baseline reading of
systolic, diastolic and mean blood pressure, heart rate
and oxygen saturation was obtained after a resting
period of 5 minutes.
Anaesthesia was induced with intravenous tramadol
2 mg kg-1, thiopentone 4-5 mg kg-1 and atracurium 0.5
mg kg-1. After tracheal intubation, patients lungs were
mechanically ventilated and anaesthesia maintained
with 60% nitrous oxide, oxygen and isoflurane (MAC 1).
A rectal suppository, either diclofenac 100 mg or
placebo, was inserted before start of surgery. Heart rate
systolic, diastolic, and mean blood pressure and oxygen
saturation were monitored throughout the maintenance
period and documented at 10 minutes interval. 
At the end of the surgery, residual neuromuscular
blockade was antagonized with neostigmine 2.5 mg and
glycopyrrolate 0.5 mg. In the recovery, a PCA pump was
connected to the patients, which contained 10mg ml-1
tramadol. The bolus dose was set at 10 mg (1ml) with a
lock out interval of 10 minutes. There was no
background infusion. Patients had been previously
instructed to use PCA to minimize pain (i.e. maintain
pain score of less than 2).
Any side effects like nausea, vomiting and respiratory
depression were monitored. The level of sedation was
assessed by using the sedation score described by
Chernik et al. (0 = awake, 1 = sleeping comfortably and
responding to vocal commands, 2 = somnolence, deep
sleep but responding to vocal commands, 3 = not
arousable, deep sleep).9 Persistent nausea (defined as
feeling of nausea for more than 30 minutes) and
vomiting more than twice was treated with intravenous
metoclopramide 10 mg bolus. If patient was unable to
obtain adequate analgesia with two consecutive dose of
tramadol, 10 mg boluses of pethidine were administered
intravenously as rescue analgesia, to minimize pain. 
Postoperatively, similar rectal suppository as given
intraoperatively (whether it was diclofenac or placebo)
was inserted 12 hourly for next 24 hours. Patients were
assessed at 6, 12 and 24 hours, postoperatively for
blood pressure, heart rate, respiratory rate, side effects
(nausea and vomiting and sedation) and for rescue
medication received. Blindness during the study period
was ensured by blinding the anaesthetist and the nurse
recording the parameters to the patient group. PCIA
pump used by the patient is called attempts. Good
attempts are those in which the drug is delivered to the
patient. Number of attempts (which include total
attempts and good attempts) and total tramadol dose
consumed (to minimize pain) was retrieved from the
PCA computer memory after 24 hours postoperatively.
Neither the pain score, nor the number of attempts at
different time intervals were assessed.
Using EpiData (version 3.1), frequencies, mean and
standard deviation of all quantitative variables were
generated. Independent samples t-test for quantitative
variable between the two groups (placebo and
diclofenac) were calculated. Repeated measures of
ANOVA were conducted to see the association within
group at different times and between groups (placebo
and diclofenac) for heart rate, systolic and diastolic
blood pressures. Association between placebo and
diclofenac group for nausea, vomiting and antiemetic
and rescue analgesia use were looked at by using
Chi-square test. Independent sample ‘t’ test was also
used to observe mean difference between groups
(placebo and diclofenac) for number of attempts
and total consumption of tramadol during 24 hours
postoperatively. A p-value of <0.05 was considered
statistically significant.
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RESULTS
There were no dropouts during the study period. The
demographic data of both groups is given in Table I.
Both groups were comparable with respect to age, body
weight, ASA physical status and duration of surgery. 
There was no difference in the systolic (SBP), diastolic
(DBP) mean arterial pressure (MAP) and heart rate
measured at corresponding time intervals (Table II), and
difference between the two groups (placebo and
diclofenac) at all times was found to be insignificant. 
The mean + SD dose of tramadol used in the first
24 hours postoperatively in the placebo-tramadol group
was 317 +153 mg and 258 +192 mg in the diclofenac-
tramadol group to relieve pain (Table III). Though
clinically, the dose was less in the diclofenac-tramadol
group, the difference was not statistically significant
(p= 0.159). When use of rescue analgesia was
compared in both the groups, 17 (49%) patients used
rescue analgesia in the placebo-tramadol group
compared to 14 (40%) patients in the diclofenac-
tramadol group, but this difference was not significant
(p=0.47). Rescue analgesia was needed in both groups
on arrival in recovery but the requirements decreased
subsequently and after 12 hours no rescue analgesia
was required in either of the groups. The average
number of attempts in the diclofenac - tramadol group
was greater (184.94 + 257) than in the placebo-
tramadol group (153.86 +177) but this was not
significant (p=0.557, Table III).
Occurrence of nausea and/or vomiting was similar in
both placebo-tramadol and diclofenac-tramadol groups.
Twelve (34%) patients had nausea in both the groups.
Vomiting occurred in 4 (11%) patients in placebo-
tramadol group and 5 (14%) in diclofenac- tramadol
group. These differences were not statistically
significant. Nineteen (54%) patients in the placebo-
tramadol group and 16 (46%) in the diclofenac group
were given antiemetic but the use was not statistically
significant. ( χ2 = 0.514, df=1, p=0.473). 
In the recovery room, none of the patient had respiratory
rate less than 10 breaths per minute. Eleven (31%) of
patients were somnolent but rousable (score of 2) in the
placebo-tramadol group compared to 14 (40%) in the
diclofenac - tramadol group. Six hours postoperatively,
only 2 patients (6%) in the placebo-tramadol group
compared to 01 (3%) in the diclofenac- tramadol group
had a score of 2. None of the patients had a score of 3
at any time during the study period.
DISCUSSION
This study has demonstrated that in patients undergoing
abdominal hysterectomy, diclofenac 100 mg rectally,
at the time of induction, did not significantly reduce
PCA tramadol consumption to obtain VAS of less than 2,
in the first 24 hours after surgery.
Tramadol has a similar efficacy to morphine when used
as an analgesic in abdominal surgery.10 It is a weak mµ
agonist with a multimodal mechanism of action. The mµ
agonist effect enhances the function of spinal
descending inhibitory pathway by inhibition of re-uptake
of both 5 Hydroxytryptamine (5HT) and nor epinephrine
together with pre-synaptic stimulation of 5HT release.11
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Table I:  Demographic characteristics and duration of surgery. Mean
(SD).
Variable Tramadol and Tramadol and 95% confidence
placebo diclofenac for the difference
(n=35) sodium group SD. (upper and 
(n=35) range)
Age (years) 43.2 (5.19) 44.3 (5.22) 1.24 (-1.34, 6.63)
Weight (kg) 67.0 (12.22) 69.7 (10.92) 2.7 (-2.83, 8.23)
Duration of anaesthesia 
(minutes) 122.6 (40.33) 122.2 ( 41.20) -9.8 (-19.98, 19.19)
ASA physical status (I:II) 21:14 17:18
Table II:  Systolic (SBP), diastolic (DBP) mean arterial pressure 
(MAP) and heart rate (HR), mean (SD).
Variable Hours after Tramadol and Tramadol and
operation placebo diclofenac sodium
(n=35) (n=35)
HR (beat/ min)
0 80.74 ± 13.4 82.60  ± 14.6
6 83.11  ± 7.8 81.57  ± 9.3 
12 84.83 ± 6.8 80.71 ± 9.4 
24 84.89 ± 7.8 81.06 ± 8.9 
SBP (mm Hg)
0 126.74 ± 14.9 128.83 ± 16.1 
6 122.40 ± 11.2 125.31 ± 10.3 
12 122.60 ± 9.9 122.34 ± 9.6 
24 123.31 ± 9.8 122.14 ± 8.8 
DBP (mm Hg)
0 72.69 ± 10.7 76.77 ± 10.0 
6 77.71 ± 7.7 78.31 ± 8.2 
12 76.80 ± 7.4 78.71 ± 7.0 
24 78.54 ± 7.48 77.83 ± 7.4 
MAP (mm Hg)
0 94.09 ± 11.0 95.06 ± 12.0 
6 92.63 ± 6.6 93.69 ± 7.9 
12 91.60 ± 7.7 93.11 ± 6.3
24 93.46 ± 7.3 92.66 ± 6.4
Table III: Dosing pattern and use of rescue analgesia. Mean (SD or 
percentage).
Tramadol and Tramadol and 95% confidence 
Variable placebo diclofenac interval for the
(n=35) sodium group difference. SD
(n=35) (upper and lower 
range)
Mean dose (mg) 317 (153) 258 (192) 1.24 (-1.34, 6.63)
Median dose (mg) 320 (153) 210 (192)
Rescue 
Analgesia used 17 (49 %) 14 (40%)
Average attempts 153.86 (176.5) 184.94 (256.8) 52.68 (-74.04, 136.21)
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It has emerged as an alternative drug to morphine for
I.V. PCA12 and has shown good efficacy after major
orthopaedic surgery.12,13 Its particular advantage is its
lesser potential of respiratory depression.14 One of the
limitations of its use in PCA is the incidence of its side
effects specially nausea and vomiting.15 One of the
ways to tackle this issue by using combination of
tramadol with other non-narcotic analgesic drugs and
thus decreases the opioid requirements and lessening
the incidence of side effects. Combinations that have
been investigated with variable results are intravenous
(I.V.) tramadol and ketorolac infusion for major
abdominal surgery, I.V. tramadol and metamizol, I.V.
tramadol          and ketoprofen, I.V. tramadol and lysine
acetyl salicylate, an injectable aspirin, and tramadol
piroxican combination.16-20
Diclofenac is an NSAID that reduces morphine
consumption after total abdominal hysterectomy.21 Most
but not all studies with narcotic NSAID combination
have shown a decrease in opioid requirement.22 Rectal
NSAID is a cost-effective method in the management of
surgical pain and has been shown to decrease
morphine consumption by 50 % in patients undergoing
abdominal hysterectomy.23,24 Not much literature is
available on the combination of these two i.e. tramadol
and diclofenac. The total morphine dosage administered
I.V. by PCA over a particular period of time has been
used as a measure of efficacy of postoperative
analgesia by several studies as used in this
methodology.25 We used an intravenous bolus dose of
tramadol of 10 mg with a lockout interval of 10 minutes
for a period of 24 hours. Background infusion as the
method would not be appropriate to evaluate a decrease
in narcotic demand.26 The routine institutional practice is
to discontinue PCA after 24 hours in order to encourage
patients to ambulate. The present results demonstrated
a slight decrease in total tramadol requests in the
diclofenac group but this did not achieve statistical
significance.
The most commonly reported side effect was nausea
(34% in each group) and vomiting (11% placebo vs.
14% in diclofenac group). Excessive sedation was not
seen in either group. Evidence supporting increased
bleeding with NSAIDS is equivocal,27 but excessive
bleeding was not reported in any of our patients.
Diarrhea, a rarely reported side effects of diclofenac
suppository was also not seen.24 This study, therefore,
did not demonstrate any significant effect of diclofenac
suppository in reducing side effects due to tramadol. Ng
et al. all demonstrated a reduction in morphine
consumption with diclofenac suppository given after
induction of anaesthesia in total abdominal
hysterectomy but side effects were not decreased.28,29
This fact has also been commented upon by other
authors with other drug combinations.21,24 It is
hypothesized that only if addition of diclofenac
decreases morphine consumption by 50%, only then a
reduction in side effects is seen.21
Negative findings have also been reported in several
other studies, with either diclofenac morphine
combination or other narcotic and non opioid
combinations of postoperative pain.29,30 In the present
study, reasons could be several. Firstly, surgery was
performed by different surgeons. Variations in dissection
and surgical techniques can lead to a difference in
postoperative analgesic requirements. The timing of
administration of analgesic drug has also been
implicated in lack of opioid sparing effect.30
Vandermeulen et al. suggested that lack of opioid sparing
effects with NSAIDs after certain operations may have
resulted because of its postoperative use only.31 Certain
pharmacokinetic characteristics, such      as low lipid
solubility and high protein binding, may also prevent the
central effect.32 This has been reported with tenoxicam.
Individual variations in pain perception and scores may
also not show a significant effect.32 As the number of
boluses requested/delivered by the PCA pump at each
hour were not assessed, therefore, the differences
between the immediate and late postoperative periods
could not be observed. Other patient factors like patient
suffering from pain but not demanding analgesia are
also a possibility.
CONCLUSION
The addition of diclofenac suppository 100 mg (inserted
after induction) to PCA with tramadol offered no
advantage in pain relief or opioid consumption for the
first 24 hours after total abdominal hysterectomy.
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